Philippines Considers New Round Of Drug Price Caps Ahead Of Review
This article was originally published in PharmAsia News
The Philippine government plans to expand its list of drugs carrying a price cap without waiting for a scheduled review of previous caps. The Health Department has a national study under way to determine candidate drugs for the next round of price reductions. The program's manager said the department also is considering whether to implement price caps every month or every other month. The first round of price controls, announced in July, ordered maximum drug retail prices on five essential drugs after drug makers voluntarily reduced the prices of 38 others. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.